Display options
Cite
Jackman M, Delrobaei M, Rahimi F, et al. Predicting Improvement in Writer's Cramp Symptoms following Botulinum Neurotoxin Injection Therapy. Tremor Other Hyperkinet Mov (N Y). 2016;6:410doi: 10.7916/D82Z15Q5.
Jackman, M., Delrobaei, M., Rahimi, F., Atashzar, S. F., Shahbazi, M., Patel, R., & Jog, M. (2016). Predicting Improvement in Writer's Cramp Symptoms following Botulinum Neurotoxin Injection Therapy. Tremor and other hyperkinetic movements (New York, N.Y.), 6410. https://doi.org/10.7916/D82Z15Q5
Jackman, Mallory, et al. "Predicting Improvement in Writer's Cramp Symptoms following Botulinum Neurotoxin Injection Therapy." Tremor and other hyperkinetic movements (New York, N.Y.) vol. 6 (2016): 410. doi: https://doi.org/10.7916/D82Z15Q5
Jackman M, Delrobaei M, Rahimi F, Atashzar SF, Shahbazi M, Patel R, Jog M. Predicting Improvement in Writer's Cramp Symptoms following Botulinum Neurotoxin Injection Therapy. Tremor Other Hyperkinet Mov (N Y). 2016 Sep 03;6:410. doi: 10.7916/D82Z15Q5. eCollection 2016. PMID: 27625900; PMCID: PMC5013165.
Copy Download .nbib Format: NLM
Share it on

Tremor Other Hyperkinet Mov (N Y). 2016 Sep 03;6:410. doi: 10.7916/D82Z15Q5. eCollection 2016.

Predicting Improvement in Writer's Cramp Symptoms following Botulinum Neurotoxin Injection Therapy.

Tremor and other hyperkinetic movements (New York, N.Y.)

Mallory Jackman, Mehdi Delrobaei, Fariborz Rahimi, S Farokh Atashzar, Mahya Shahbazi, Rajni Patel, Mandar Jog

Affiliations

  1. Lawson Health Research Institute, London, ON, Canada.
  2. Faculty of Electrical Engineering, K. N. Toosi University of Technology, Tehran, Iran.
  3. Department of Electrical and Computer Engineering, Bonab University, Bonab, East Azerbaijan, Iran.
  4. Department of Electrical and Computer Engineering, Western University, London, ON, Canada.
  5. Lawson Health Research Institute, London, ON, Canada; Department of Electrical and Computer Engineering, Western University, London, ON, Canada.
  6. Lawson Health Research Institute, London, ON, Canada; Department of Clinical Neurological Sciences, Western University, London, ON, Canada.

PMID: 27625900 PMCID: PMC5013165 DOI: 10.7916/D82Z15Q5

Abstract

INTRODUCTION: Writer's cramp is a specific focal hand dystonia causing abnormal posturing and tremor in the upper limb. The most popular medical intervention, botulinum neurotoxin type A (BoNT-A) therapy, is variably effective for 50-70% of patients. BoNT-A non-responders undergo ineffective treatment and may experience significant side effects. Various assessments have been used to determine response prediction to BoNT-A, but not in the same population of patients.

METHODS: A comprehensive assessment was employed to measure various symptom aspects. Clinical scales, full upper-limb kinematic measures, self-report, and task performance measures were assessed for nine writer's cramp patients at baseline. Patients received two BoNT-A injections then were classified as responders or non-responders based on a quantified self-report measure. Baseline scores were compared between groups, across all measures, to determine which scores predicted a positive BoNT-A response.

RESULTS: Five of nine patients were responders. No kinematic measures were predictably different between groups. Analyses revealed three features that predicted a favorable response and separated the two groups: higher than average cramp severity and cramp frequency, and below average cramp latency.

DISCUSSION: Non-kinematic measures appear to be superior in making such predictions. Specifically, measures of cramp severity, frequency, and latency during performance of a specific set of writing and drawing tasks were predictive factors. Since kinematic was not used to determine the injection pattern and the injections were visually guided, it may still be possible to use individual patient kinematics for better outcomes.

Keywords: Writer’s cramp; botulinum toxin; focal hand dystonia; kinematics

Conflict of interest statement

Funding: The study was sponsored by a grant from Allergan Inc. and Botox® was provided in kind. Conflict of Interest: Dr. Mandar Jog is a consultant for Allergan. Ethics Statement: This study was perf

References

  1. J Neurol Neurosurg Psychiatry. 2007 Mar;78(3):264-70 - PubMed
  2. J Neurol Neurosurg Psychiatry. 1996 Aug;61(2):172-5 - PubMed
  3. J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1688-91 - PubMed
  4. Trends Neurosci. 1990 Apr;13(4):148-53 - PubMed
  5. Neurology. 2008 Jan 22;70(4):304-15 - PubMed
  6. Mov Disord. 2007 Jun 15;22(8):1102-9 - PubMed
  7. Control Clin Trials. 1981 Jun;2(2):93-113 - PubMed
  8. Neurology. 1993 Jan;43(1):183-5 - PubMed
  9. J Neurol Neurosurg Psychiatry. 1999 Jul;67(1):90-3 - PubMed
  10. J Clin Exp Neuropsychol. 1999 Aug;21(4):559-66 - PubMed
  11. Acad Emerg Med. 2007 Jul;14(7):662-8 - PubMed
  12. Med Devices (Auckl). 2012;5:97-101 - PubMed
  13. J Hand Ther. 2009 Apr-Jun;22(2):163-70; quiz 171 - PubMed
  14. J Neuroeng Rehabil. 2016 Feb 18;13:15 - PubMed
  15. Int J Clin Pract. 2005 Sep;59(9):1088-90 - PubMed
  16. Clin Neurol Neurosurg. 2009 Feb;111(2):161-4 - PubMed
  17. Hum Mov Sci. 2011 Aug;30(4):807-17 - PubMed
  18. J Neurol Neurosurg Psychiatry. 1989 Mar;52(3):355-63 - PubMed
  19. Neurology. 2001 Jun 12;56(11):1523-8 - PubMed
  20. Clin Neurophysiol. 2010 Nov;121(11):1898-907 - PubMed
  21. J Hand Ther. 2004 Jul-Sep;17(3):349-63 - PubMed
  22. J Neural Transm (Vienna). 2008;115(4):653-6 - PubMed
  23. Restor Neurol Neurosci. 2013;31(5):533-42 - PubMed
  24. Rev Neurol (Paris). 2003 Oct;159(10 Pt 1):923-7 - PubMed
  25. Parkinsonism Relat Disord. 2013 Jun;19(6):611-6 - PubMed
  26. J Behav Ther Exp Psychiatry. 1982 Mar;13(1):69-72 - PubMed

Publication Types